An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Evolving First-Line Treatment Strategies for uHCC.

Now Viewing

EP: 2.An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.

EP: 3.Academic Perspectives on Front-line Nivolumab/ Ipilimumab Therapy for uHCC.

EP: 4.Navigating Between Front-line Systemic Therapies in uHCC.

EP: 5.Patient Considerations for Front-line Systemic Immunotherapies in uHCC.

EP: 6.Future Outlook in Front-line Treatment for uHCC.

Video content above is prompted by the following:

Review the ongoing phase 3 CheckMate 9DW investigating nivolumab + ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib in 1L uHCC.

Recent Videos

Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_

The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns

Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC

1L Treatment for Advanced NSCLC

Recap: ELCC 2025 Highlights

Presented at ELCC 2025: Key Takeaways From KRYSTAL-7

ELCC 2025: Insights From the MARIPOSA Study

LAURA Study: NGS Testing in Diagnosis of NSCLC

Exploring Updates From KEYNOTE-799 at ELCC 2025

Long-Term Outcomes of Ruxolitinib Therapy in Patients With cGVHD